A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma.

Trial Profile

A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Cediranib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2011 Planned end date changed from Jun 2009 to Dec 2011 as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Planned end date changed from 1 Apr 2006 to 1 Jun 2009.
    • 19 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top